Descriptive pharmaco-epidemiological study on the use of Symbicort® Turbuhaler® in the treatment of asthma in France and impact of a new treatment strategy on compliance and asthma control FRESH-PEF188-en Pascal PIEDBOIS Descriptive pharmaco-epidemiological study on the use of Symbicort® Turbuhaler® in the treatment of asthma in France and impact of a new treatment strategy on compliance and asthma control SYMBIOSE FRESH-PEF188-en 188 FRESH-PEF188 Florence THOMAS-DELECOURT Pascal PIEDBOIS ASTRAZENECA (FRANCE) Epidemiology France Portal (PEF) ASTRAZENECA (FRANCE) null Florence;THOMAS-DELECOURT Pascal;PIEDBOIS Symbicort® Turbuhaler® cohort Pulmonary medicine Healthcare system determinants: Use of care Healthcare system determinants Describe the characteristics of asthmatic patients treated with Symbicort Turbuhaler Compare the characteristics of patients treated according to the therapeutic strategy Evaluate the level of asthma control and compliance with treatment of patients treated with Symbicort Turbuhaler null France Individuals Patients population Male Female Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Patients diagnosed as asthmatic by the physician and treated for this pathology with Symbicort Turbuhaler Clinical data Participant-reported health data Health event/morbidity Quality of life/health perception Other Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Converting or copying information into a structured record Interview with the participant (including clinical) Observational Study Observational Study 1844 Unknown To be defined Access on specific project only